十二烷基肼 | 2656-75-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 十二烷基肼
• 英文名称: n-dodecylhydrazine
• 英文别名: dodecyl hydrazine；dodecylhydrazine；1-Hydrazino-dodecan；Dodecyl-hydrazin；Dodecyl-hydrazine
• CAS: 2656-75-9
• 化学式: C₁₂H₂₈N₂
• 分子量: 200.368
• InChiKey: OKMQERWDFNIGLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  14
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  十二烷基肼 生成 (2,4-dipentyl-phenoxy)-acetic acid-(1-dodecyl-5-oxo-2,5-dihydro-1H-pyrazol-3-ylamide)
  参考文献：
  名称：

  1-alkyl-3-acylamido-5-pyrazolone couplers for color photography

  摘要：

  公开号：

  US02865751A1
• 作为产物：
  描述：

  1-氯十二烷 在 乙醇 、 肼 作用下， 生成 十二烷基肼 、 N,N-didodecyl-hydrazine
  参考文献：
  名称：

  Westphal, Chemische Berichte, 1941, vol. 74, p. 775

  摘要：

  DOI：

文献信息

• Studies on Hypolipidemic Agents. II. Synthesis and Pharmacological Properties of Alkylpyrazole Derivatives
  作者：KUNIO SEKI、JUNICHI ISEGAWA、MINORU FUKUDA、MASAHIKO OHKI

  DOI：10.1248/cpb.32.1568

  日期：1984.4.25

  A series of 5-alkylpyrazole derivatives was synthesized and evaluated for potent hypolipidemic activity in rats. Many pyrazole derivatives with an alkyl group at the 5 position of the pyrazole ring were found to possess high hypolipidemic activity. Homologation of the alkyl chain led to marked increase in activity, but introduction of other substituents at other sites on the pyrazole ring failed to

  合成了一系列的5-烷基吡唑衍生物，并对其在大鼠中的有效降血脂活性进行了评估。发现许多在吡唑环的5位具有烷基的吡唑衍生物具有高降血脂活性。烷基链的同源性导致活性显着增加，但是在吡唑环上其他位点引入其他取代基未能增强活性。另外，用异恶唑环取代吡唑环导致活性显着降低。在测试的化合物中，5-n-十三烷基吡唑-3-羧酸（5k）表现出最有利的活性谱，并且与氯贝特一样有效。该化合物5k在急性试验（LD50 = 10.0g / kg）中显示出相当低的毒性，因此目前正在接受进一步的药理评估。
• METHOD FOR PRODUCING POLYMERIZABLE COMPOUND
  申请人：DIC Corporation

  公开号：US20180354922A1

  公开（公告）日：2018-12-13

  The polymerizable compound has a hydrazone moiety. The present invention also provides a polymerizable composition in which discoloration and reduction of aligning property do not easily occur. Furthermore, the present invention provides a polymer obtained by polymerizing a polymerizable composition containing a compound obtained by the production method and an optically anisotropic body using the polymer. The present invention provides a method for producing a polymerizable compound including a step of reacting a compound represented by General Formula (I-B-a) with a compound represented by General Formula (I-B-b) to obtain a compound represented by General Formula (I-C), and provides a composition which contains a compound obtained by this production method.

  这种可聚合化合物具有醛肟基团。本发明还提供了一种可聚合组合物，其中不容易发生变色和对齐性能降低。此外，本发明提供了一种通过聚合含有通过生产方法获得的化合物的可聚合组合物以及使用聚合物制备光学各向异性体的聚合物。本发明提供了一种生产可聚合化合物的方法，包括将通式（I-B-a）表示的化合物与通式（I-B-b）表示的化合物反应以获得通式（I-C）表示的化合物的步骤，并提供了包含通过这种生产方法获得的化合物的组合物。
• 2-Nitroimidazole derivatives
  申请人：Gruppo Lepetit S.p.A.

  公开号：US03954789A1

  公开（公告）日：1976-05-04

  2-Nitroimidazole derivatives of the general formula ##SPC1## Wherein R is a lower alkyl group and Y is a member of the group consisting of --CH.sub.2 OH, --CHO, CH.sub.3 CO--, vinyl, formylvinyl, styryl, substituted iminomethyl, 2-benzimidazolyl and 5-amino-1,3,4-thiadiazol-2-yl. The term "lower alkyl" designates aliphatic groups of from 1 to 4 carbon atoms; the term "substituted iminomethyl" designates nitrogen-containing functional derivatives of the aldehydic group. The compounds have antimicrobial activity.

  2-硝基咪唑衍生物的一般公式如下：其中R是较低的烷基基团，Y是--CH₂OH、--CHO、CH₃CO--、乙烯、甲酰乙烯、苯乙烯、取代亚硝基甲基、2-苯并咪唑基和5-氨基-1,3,4-噻二唑-2-基中的一种。术语“较低烷基”指的是由1至4个碳原子组成的脂肪族基团；术语“取代亚硝基甲基”指的是醛基的含氮功能衍生物。这些化合物具有抗微生物活性。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。
• Nitrogen-containing heterocyclic compounds and medicinal use thereof
  申请人：Habashita Hiromu

  公开号：US20070167459A1

  公开（公告）日：2007-07-19

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  式(I)和(II)所代表的化合物、其盐、N-氧化物或溶剂合物、或其前药，以及包含它们的制药组合物具有CXCR4调节作用，它们对各种炎症性疾病、各种过敏性疾病、艾滋病毒感染、或再生治疗剂具有治疗和预防作用。(其中环A代表可能具有取代基的含氮杂环基团；环B代表可能具有取代基的同环基团或可能具有取代基的杂环基团；Y代表可能具有取代基的碳氢基团、可能具有取代基的杂环基团、可能被保护的氨基、可能被保护的羟基或可能被保护的巯基；T代表环A或可能被保护的氨基。)